Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–35. doi:10.1056/NEJMra1405427.
Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health. 2014;2(8):e453–9. doi:10.1016/S2214-109X(14)70245-1.
Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152. doi:10.1371/journal.pmed.1002152.
Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99(2):131–8. doi:10.1093/oxfordjournals.aje.a121593.
Vynnycky E. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol. 2000;152(3): 247–63. doi:10.1093/aje/152.3.247.
Uplekar M, Weil D, Lönnroth K, Jaramillo E, Lienhardt C, Dias HM et al. WHO’s new end TB strategy. Lancet. 2015;385(9979):1799–801. doi:10.1016/S0140-6736(15)60570-0.
Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, de Vries G, Diel R et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928–52. doi:10.1183/09031936.00214014.
WHO operational handbook on tuberculosis. Module 1: prevention – tuberculosis preventive treatment, second edition. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/378535).
The V-QUIN MDR TRIAL: A randomized controlled trial of six months of daily levofloxacin for the prevention of tuberculosis among household contacts of patients with multi-drug resistant tuberculosis. Camperdown: The Australian New Zealand Clinical Trials Registry; 2016 (https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369817).
A phase III cluster randomized placebo-controlled trial to assess the efficacy of preventive therapy in child and adolescent contacts of MDR-TB (TB-CHAMP). Stellenbosch: Stellenbosch University Dept of Paediatrics and Child Health; 2016 (https://www.isrctn.com/ISRCTN92634082).
Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714. doi:10.7448/IAS.19.1.20714.
Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010; CD000171. doi:10.1002/14651858.CD000171.pub3.
Chaisson LH, Saraceni V, Cohn S, Seabrook D, Cavalcante SC, Chaisson RE et al. CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV. AIDS. 2020;34(1):139–47. doi:10.1097/ QAD.0000000000002398.
Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomized double-blind, placebo-controlled trial. Lancet. 2014;384(9944):682–90. doi:10.1016/S0140-6736(14)60162-8.
The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22. doi:10.1056/NEJMoa1507198.
Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB et al. Effect of isoniazid preventive therapy on risk of death in West African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9. doi:10.1016/S2214-109X(17)30372-8.
Bruins WS, van Leth F. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infecti Dis. 2017;49(3):161–9. doi:10.1080/23744235.2016.1262059.
Churchyard G, Cárdenas V, Chihota V, Mngadi K, Sebe M, Brumskine W et al. Annual tuberculosis preventive therapy for persons with HIV infection: a randomized trial. Ann Intern Med. 2021;174(10):1367–76. doi:10.7326/M20-7577.
Getahun H, Sculier D, Sismanidis C, Grzemska M, Raviglione M. Prevention, diagnosis, and treatment of tuberculosis in children and mothers: evidence for action for maternal, neonatal, and child health services. J Infect Dis. 2012;205(suppl 2):S216–27. doi:10.1093/infdis/jis009.
Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomized controlled trial. BMJ. 2007;334(7585):136. doi:10.1136/bmj.39000.486400.55.
Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011;365(1):21–31. doi:10.1056/NEJMoa1011214.
Gray DM, Workman LJ, Lombard CJ, Jennings T, Innes S, Grobbelaar CJ et al. Isoniazid preventive therapy in HIVinfected children on antiretroviral therapy: a pilot study. Int J Tuberc Lung Dis. 2014;18(3):322–7. doi:10.5588/ ijtld.13.0354.
Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard CJ, Zar HJ. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax. 2011;66(6):496–501. doi:10.1136/thx.2010.156752.
Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76. doi:10.1183/13993003.01245-2015.
Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-Faussett P et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med. 2014;370(4):301–10. doi:10.1056/ NEJMoa1214289.
Ntinginya NE. A randomized double blind placebo controlled trial of rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (Report No. NCT04600167). Bethesda (MD): Clinical Trials.gov; 2023 (https://clinicaltrials.gov/study/NCT04600167).
Bhargava A, Bhargava M, Meher A, Benedetti A, Velayutham B, Sai Teja G et al. Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomized, controlled trial. Lancet. 2023;402(10402):627– 40. doi:10.1016/S0140-6736(23)01231-X.
Denholm JT, Matteelli A, Reis A. Latent tuberculous infection: ethical considerations in formulating public health policy. Int J Tuberc Lung Dis. 2015;19(2):137–40. doi:10.5588/ijtld.14.0543.
Resolution WHA61.17. Health of migrants. In: Sixty-first World Health Assembly, Geneva: 19–24 May 2008, Resolutions and decisions; annexes (WHA61/2008/REC/1):23–5. Geneva: World Health Organization; 2008 (apps.who.int/gb/ebwha/pdf_files/WHA62-REC1/WHA62_REC1-en.pdf).
Kass NE. An ethics framework for public health. Am J Public Health. 2001;91(11):1776–82. doi: 10.2105/ ajph.91.11.1776.
Cranmer LM, Njuguna IN, LaCourse SM, Figueroa J, Gillespie S, Maleche-Obimbo E et al. Brief report: performance of tuberculosis symptom screening among hospitalized ART-naive children with HIV in Kenya. J Acqui Immune Defic Syndr. 2022;91(3):280–4. doi:10.1097/QAI.0000000000003060.
Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8(1):e1000391. doi:10.1371/journal. pmed.1000391.
Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO’s recommended foursymptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(9):e515–23. doi:10.1016/S2352-3018(18)30137-1.
Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W et al. Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS. 2014;28(10):1463–72. doi:10.1097/QAD.0000000000000278.
Nguyen DTM, Bang ND, Hung NQ, Beasley RP, Hwang LY, Graviss EA. Yield of chest radiograph in tuberculosis screening for HIV-infected persons at a district-level HIV clinic. Int J Tuberc Lung Dis. 2016;20(2):211–7. doi:10.5588/ijtld.15.0705.
Cranmer L, Pavlinac P, Njuguna I, Otieno V, Maleche-Obimbo E, Moraa H et al. Performance of WHO TB symptom screen in hospitalized HIV-positive Kenyan children. J Acquir Immune Defic Syndr. 2022; 91(3): 280–4. doi:10.1097/QAI.000000000000306.
Kruk A, Gie RP, Schaaf HS, Marais BJ. Symptom-based screening of child tuberculosis contacts: improved feasibility in resource-limited settings. Pediatrics. 2008;121(6):e1646–52. doi:10.1542/peds.2007-3138.
Triasih R, Robertson CF, Duke T, Graham SM. A prospective evaluation of the symptom-based screening approach to the management of children who are contacts of tuberculosis cases. Clin Infect Dis. 2015;60(1):12–8. doi:10.1093/cid/ciu748.
Mandalakas AM, Hesseling AC, Gie RP, Schaaf HS, Marais BJ, Sinanovic E. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax. 2013;68(3):247–55. doi:10.1136/thoraxjnl-2011-200933.
van’t Hoog A, Langendam MW, Cobelens FGJ, Sinclair D, Leeflang M, Lönnroth K. A systematic review of the sensitivity and specificity of symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative persons and persons with unknown HIV status. Cochrane Database Syst Rev. 2022;2022(3): CD010890. doi:10.1002/14651858.CD010890.pub2.
Assefa Y, Woldeyohannes S, Gelaw YA, Hamada Y, Getahun H. Screening tools to exclude active pulmonary TB in high TB burden countries: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2019;23(6):728– 34. doi:10.5588/ijtld.18.0547.
Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28– 106. PMID:4903501.
Gao L, Li X, Liu J, Wang X, Lu W, Bai L et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2017;17(10):1053–61. doi:10.1016/S1473-3099(17)30402-4.
Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45–55. doi:10.1016/S1473-3099(11)70210-9.
Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M et al. The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One. 2011;6(3):e17984. doi:10.1371/journal.pone.0017984.
Mathad JS, Bhosale R, Balasubramanian U, Kanade S, Mave V, Suryavanshi N et al. Quantitative IFN-γ and IL-2 response associated with latent tuberculosis test discordance in HIV-infected pregnant women. Am J Respir Crit Care Med. 2016;193(12):1421–8. doi:10.1164/rccm.201508-1595OC.
McCarthy KM, Scott LE, Gous N, Tellie M, Venter WDF, Stevens WS et al. High incidence of latent tuberculous infection among South African health workers: an urgent call for action. Int J Tuberc Lung Dis. 2015;19(6):647– 53. doi:10.5588/ijtld.14.0759.
Sharma SK, Vashishtha R, Chauhan LS, Sreenivas V, Seth D. Comparison of TST and IGRA in diagnosis of latent tuberculosis infection in a high TB-burden setting. PLoS One. 2017;12(1):e0169539. doi:10.1371/ journal.pone.0169539.
Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P et al. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189(1):77–87. doi:10.1164/rccm.201302-0365OC.
Chaisson L, Saraceni V, Cohn S, Cavalcante S, Chaisson RE, Golub J et al. CD4 count-based guidelines for tuberculin skin testing and tuberculosis preventive therapy in people living with HIV. Abstract 3274. In: Proceedings of the 10th IAS Conference on HIV Science, Mexico City, Mexico, 21–24 July 2019 (http://programme.ias2019.org/Abstract/Abstract/3724).
Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012. doi:10.1371/journal.pmed.1001012.
Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst Rev. 2017;CD006418. doi:10.1002/14651858.CD006418.pub3.
Smieja M, Marchetti C, Cook D, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 1999;CD001363. doi:10.1002/14651858.CD001363.
Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248. doi:10.7326/M17-0609.
Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3(10):847–50. PMID:10524579.
Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB- and HIV-prevalence settings – 2015 update (WHO/HTM/TB/2015.15/ WHO/HIV/2015.13) Geneva: World Health Organization; 2015 (https://apps.who.int/iris/bitstream/handle/10665/174052/9789241508872_eng.pdf).
Den Boon S, Matteelli A, Ford N, Getahun H. Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. AIDS. 2016;30(5):797–801. doi:10.1097/QAD.0000000000000985.
Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11–20. doi:10.1056/NEJMoa1005136.
Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30(10):1607–15. doi:10.1097/QAD.0000000000001098.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66. doi:10.1056/ NEJMoa1104875.
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169(3):247. doi:10.1001/jamapediatrics.2014.3158.
Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161(6):419. doi:10.7326/M14-1019.
Galli L, Lancella L, Tersigni C, Venturini E, Chiappini E, Bergamini B et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian Register of Pediatric Tuberculosis. Int J Mol Sci. 2016;17(6):960. doi:10.3390/ijms17060960.
Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45(6):715– 22. doi:10.1086/520983.
van Zyl S, Marais BJ, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis. 2006;10(1):13–8. PMID:16466031.
Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. New Eng J Med. 2019;380(11):1001–11. doi:10.1056/ NEJMoa1806808.
Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H et al. Four months of rifampicin or nine months of isoniazid for latent tuberculosis in adults. New Engl J Med. 2018;379(5):440–53. doi:10.1056/ NEJMoa1714283.
Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018;379(5):454–63. doi:10.1056/NEJMoa1714284.
Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149(10):689–97. doi:10.7326/0003-4819-149-10-200811180-00003.
Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170(4):445–9. doi:10.1164/rccm.200404-478OC.
Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K et al. Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere trials. Ann Am Thorac Soc. 2018;15(5):570– 80. doi:10.1513/AnnalsATS.201704-326OC.
Centers for Disease Control and Prevention. Phase I/II dose finding and safety study of rifapentine and isoniazid in HIV-infected and HIV-uninfected children with latent tuberculosis infection (Report No. NCT03730181). Bethesda (MD): Clinical Trials.gov; 2023 (https://clinicaltrials.gov/study/NCT03730181).
Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167(10):689. doi:10.7326/M17-1150.
Lim RK, Semitala FC, Atuhumuza E, Sabiti L, Namakula-Katende J, Muyindike WR et al. Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda. PLoS One. 2021;16(2):e0246113. doi:10.1371/journal.pone.0246113.
Hussain H, Jaswal M, Farooq S, Safdar N, Madhani F, Noorani S et al. Scale-up of rifapentine and isoniazid for tuberculosis prevention among household contacts in 2 urban centers: an effectiveness assessment. Clin Infect Dis. 2023;77(4):638–44. doi:10.1093/cid/ciad245.
Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Lancet HIV. 2020;7(6):e401–9. doi:10.1016/S2352-3018(20)30032-1.
Lin KY, Sun HY, Yang CJ, Lu PL, Lee YT, Lee NY et al. Treatment responses to integrase strand-transfer inhibitor-containing antiretroviral regimens in combination with short-course rifapentine-based regimens for latent tuberculosis infection among people with human immunodeficiency virus. Clin Infect Dis. 2023;78(5):1295–303. doi:10.1093/cid/ciad730.
Chaisson LH, Semitala FC, Nangobi F, Steinmetz S, Marquez C, Armstrong DT et al. Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine. AIDS. 2023;37(7):1097–101. doi:10.1097/QAD.0000000000003508.
Weld E, Salles I, Nonyane A, Sebe M, Beattie T, Mapendere M et al. DOLPHIN TOO: weekly rifapentine and isoniazid for tuberculosis prevention in ART naive people with HIV initiating dolutegravir-based ART: a phase 1/2 study. Lancet HIV. 2020;7(6):e401–9. doi:10.1016/S2352-3018(20)30032-1.
Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–85. doi:10.1093/ jac/dkt483.
Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T et al. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61(8):1322–7. doi:10.1093/cid/civ464.
Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Onyango-Makumbi C et al. Randomized trial of safety of isoniazid preventive therapy during or after pregnancy (Abstract No: 142LB). In: Critical issues in women’s health and early treatment of pediatric HIV infection. Conference on Retroviruses and Opportunistic Infections, Boston (MA); 2018 (http://www.croiconference.org/sessions/randomized-trial-safety-isoniazid-preventive-therapy-during-or-after-pregnancy).
Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):1333–46. doi:10.1056/ NEJMoa1813060.
Taylor AW, Mosimaneotsile B, Mathebula U, Mathoma A, Moathlodi R, Theebetsile I et al. Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. Infect Dis Obstet Gynecol. 2013;2013:1–5. doi:10.1155/2013/195637.
Salazar-Austin N, Cohn S, Lala S, Waja Z, Dooley KE, Hoffmann CJ et al. Isoniazid preventive therapy and pregnancy outcomes in HIV-infected women in the Tshepiso cohort. Clin Infect Dis. 2019;71(6):1419–26. doi:10.1093/cid/ciz1024.
Kalk EK, Heekes A, Mehta U, de Waal R, Jacob N, Cohen K et al. Programmatic review of safety and effectiveness of isoniazid preventive therapy in HIV-infected pregnant women on ART in routine care. Reprod Toxicol. 2018;80:155. doi:10.1093/cid/ciz1224.
Gupta A, Singh P, Aaron L, Montepiedra G, Chipato T, Stranix-Chibanda L et al. Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. Lancet Child Adolesc Health. 2023;7(10):708–17. doi:10.1016/S2352-4642(23)00174-8.
Chihota V, Waggie Z, Cardenas V, Martinson N, Yimer G, Garcia-Basteiro AL et al. OA07-638-19. Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment during pregnancy. Int J Tuberc Lung Dis. 2021;25(10(Suppl_2):S61–2 (https://theunion.org/sites/default/files/2021-10/UNION2021_Abstracts_High.pdf).
Huang CC, Becerra MC, Calderon R, Contreras C, Galea J, Grandjean L et al. Isoniazid preventive therapy in contacts of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2020;202(8):1159–68. doi:10.1164/ rccm.201908-1576OC.
Takizawa T, Hashimoto K, Minami T, Yamashita S, Owen K. The comparative arthropathy of fluoroquinolones in dogs. Hum Exp Toxicol. 1999;18(6):392–9. doi:10.1191/096032799678840237.
Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use – safety report. Pediatr Infect Dis J. 1997;16(1):127–9; discussion 160–2. doi:10.1097/00006454-199701000-00036.
Warren RW. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. Pediatr Infect Dis J. 1997;16(1):118–22; discussion 123–6. doi:10.1097/00006454-199701000-00034.
Acar S, Keskin-Arslan E, Erol-Coskun H, Kaya-Temiz T, Kaplan YC. Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: a systematic review and meta-analysis. Reprod Toxicol. 2019;85:65–74. doi:10.1016/j.reprotox.2019.02.002.
Levofloxacin. In: Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development; 2006 (http://www.ncbi.nlm.nih.gov/books/NBK501002/).
Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics. 2002;109(5):765– 71. doi:10.1542/peds.109.5.765.
Baker JJ, Nahar R, Petroelje BK, Goswami ND, Lardizabal AA. Fluoroquinolone-resistant latent tuberculosis infection: A literature review and case series of 5 patients treated with linezolid monotherapy. J Clin Tuberc Other Mycobact Dis. 2023;32:100376. doi:10.1016/j.jctube.2023.100376.
Bamrah S, Brostrom R, Dorina F, Setik L, Song R, Kawamura LM et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009–2012. Int J Tuberc Lung Dis. 2014;18(8):912–8. doi:10.5588/ijtld.13.0028.
Sotgiu G, Matteelli A, Getahun H, Girardi E, Sañé Schepisi M, Centis R et al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J. 2015;45(4):1170–3. doi:10.1183/09031936.00216814.
Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12(5):744–51. doi:10.3201/eid1205.050681.
Den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(8):1065–71. doi:10.5588/ijtld.15.0908.
The Aurum Institute NPC. A randomized trial comparing treatment completion of daily rifapentine & isoniazid for one month (1HP) to weekly rifapentine & isoniazid for 3 months (3HP) in persons living with HIV and in HIV-negative household contacts of recently diagnosed tuberculosis patients, The “One To Three” trial (Report No. NCT05118490). Bethesda (MD): Clinical Trials.gov; 2024 (https://clinicaltrials.gov/study/NCT05118490).
Johns Hopkins University. Safety and tolerability of ultra-short course rifapentine and isoniazid (1HP) for prevention of tuberculosis in HIV-uninfected individuals (Report No. NCT04703075). Bethesda (MD): Clinical Trials.gov; 2024 (https://clinicaltrials.gov/study/NCT04703075).
Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G et al. Pharmacokinetics and safety of 3 months of weekly rifapentine and isoniazid for tuberculosis prevention in pregnant women. Clin Infect Dis. 2022;74(9):1604–13. doi:10.1093/cid/ciab665.
Ammerman NC, Nuermberger EL, Owen A, Rannard SP, Meyers CF, Swindells S. Potential impact of longacting products on the control of tuberculosis: preclinical advancements and translational tools in preventive treatment. Clin Infect Dis. 2022;75(Suppl_4):S510–6. doi:10.1093/cid/ciac672.
Обратная связь